1.
Rev Esp Enferm Dig
; 2023 Oct 26.
Artículo
en Inglés
| MEDLINE
| ID: mdl-37882200
RESUMEN
An increasing use of immunomodulatory drugs has led to a corresponding increase in treatment-related pathologies such as inflammatory bowel disease. Here, we present a case of ulcerative colitis due to Obinutuzumab, an antiCD20 monoclonal approved for the treatment of Non-Hodgkin lymphomas.